Stay updated with breaking news from Mablink Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lazard and Elaia Partners plan to launch a late-stage and growth equity fund focused on Europe and managed by a new jointly owned asset management firm based in Paris ...
The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
The discovery collab between Lilly and Prism, worth north of $600 million, promises to yield fresh targets that are readily druggable with small molecules.
Notably, the Lilly deal is also expected to extend Beam’s cash runway to the second half of 2026.
The stock market gave up gains Thursday morning, as small caps and the IBD 50 also lagged amid a day full of events to watch.